MT-TM

Summary

MT-TM (mitochondrially encoded tRNA-Met (AUA/G), HGNC:7492) is a mitochondrial tRNA gene on chromosome mitochondria.

At a glance

• Gene type: non-coding (Mt_tRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:7492
Approved symbol	MT-TM
Name	mitochondrially encoded tRNA-Met (AUA/G)
Location	mitochondria
Locus type	RNA, transfer
Status	Approved
Aliases	trnM
Ensembl gene	ENSG00000210112
Ensembl biotype	Mt_tRNA
OMIM	590065
Entrez	4569
RNAcentral	URS000006E464 — tRNA, 68 nt, 30 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 Mt_tRNA

ENST00000387377

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000387377 — 1 exons

Exon	Start	End
ENSE00001544493	4402	4469

Expression profiles

Bgee: expression breadth ubiquitous, 118 present calls, max score 99.77.

Top tissues by expression

118 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
prefrontal cortex	UBERON:0000451	99.77	gold quality
apex of heart	UBERON:0002098	99.77	gold quality
caudate nucleus	UBERON:0001873	99.72	gold quality
skeletal muscle tissue	UBERON:0001134	99.68	gold quality
frontal cortex	UBERON:0001870	99.68	gold quality
right frontal lobe	UBERON:0002810	99.67	gold quality
putamen	UBERON:0001874	99.66	gold quality
substantia nigra	UBERON:0002038	99.63	gold quality
amygdala	UBERON:0001876	99.61	gold quality
Ammon’s horn	UBERON:0001954	99.55	gold quality
nucleus accumbens	UBERON:0001882	99.53	gold quality
sural nerve	UBERON:0015488	99.49	gold quality
anterior cingulate cortex	UBERON:0009835	99.48	gold quality
hypothalamus	UBERON:0001898	99.47	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	99.33	gold quality
heart left ventricle	UBERON:0002084	99.04	gold quality
adult mammalian kidney	UBERON:0000082	98.72	gold quality
cerebral cortex	UBERON:0000956	98.55	gold quality
vermiform appendix	UBERON:0001154	98.55	gold quality
right hemisphere of cerebellum	UBERON:0014890	98.53	gold quality
cerebellar hemisphere	UBERON:0002245	98.19	gold quality
right adrenal gland cortex	UBERON:0035827	97.89	gold quality
brain	UBERON:0000955	97.71	gold quality
gastrocnemius	UBERON:0001388	97.36	gold quality
muscle of leg	UBERON:0001383	97.09	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	96.82	gold quality
right adrenal gland	UBERON:0001233	96.81	gold quality
right atrium auricular region	UBERON:0006631	96.51	gold quality
kidney	UBERON:0002113	96.47	gold quality
adrenal gland	UBERON:0002369	96.34	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.25
E-HCAD-30	no	109.87

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 11)

• Mitochondrial tRNAMet is exported to the cytoplasm and associates specifically with immunopurified Argonaute 2 protein expressed in human 293 cells. (PMID:15872185)
• The noncoding mitochondrial sequence alteration (A4401G) at the junction of tRNA(Met) and tRNA(Gln) alters mitochondrial function, implicating this mutation in the pathogenesis of left ventricular hypertrophy in Chinese hypertensives. (PMID:18701880)
• The 5-formylcytidine modification contributes to tRNAMet’s anticodon domain structure, thermodynamic properties and its ability to bind codons AUA and AUG in translational initiation and elongation. (PMID:18927116)
• Approximately 30% reductions in the steady-state levels of tRNA(Met) and tRNA(Gln) were observed in 2 lymphoblastoid cell lines carrying the 4401A>G mutation compared with 2 control cell lines lacking this mutation. (PMID:19546379)
• The unique post-transcriptional modification, 5-formylcytidine, at the wobble position 34 (f5C34) enabled P-site codon binding to these normally isoleucine codons, expanding codon recognition to the non-traditional AUU and AUC as well as AUA. (PMID:21168417)
• The occurrence of the 4435A>G tRNAMet mutation in two genetically unrelated families affected by hypertension indicates that this mutation is involved in hypertension. (PMID:21694735)
• A maternal history of hypertension was present in 57.1% of patients with tRNAMet mutations and only 20.0% of patients without mutations. (PMID:23563319)
• The mitochondrial tRNA(Met) 4454T > C variant may not have an effect on clinical expression of essential hypertension. (PMID:23627313)
• A4401G mutations in the glycineand methioninetRNA genes are reported to be pathogenic in a family with hypertension. (PMID:28259969)
• findings suggested the pathogenic mechanism leading to an impaired oxidative phosphorylation in cells carrying the hypertension-associated m.4435A–>G mutation in the tRNAMet gene. (PMID:29222331)
• Next-generation sequencing of the mitochondrial genome revealed a novel m.4412G>A variant at high heteroplasmy levels in muscle that fulfils all accepted criteria for pathogenicity including segregation within single muscle fibres, thus broadening the genotypic and phenotypic landscape of mitochondrial tRNA-related disease. (PMID:31022467)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.